# Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA

> **NCT07291063** · — · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Anti-PD-1/PD-L1 antibody
- **DRUG:** Gemcitabine and Cisplatin Chemotherapy

## Key facts

- **NCT ID:** NCT07291063
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-19
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07291063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07291063, "Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07291063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*